European journal of nuclear medicine and molecular imaging · 2026
PD-L1 PET/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smit Jasper, Borm Frank J, Gerards Nienke R, Wiegers Sanne E, Holden Daniel, Leung David, Grootendorst Diederik J, Windhorst Bert, Nabulsi Nabeel, Cai Zhengxin, Huang Yiyun, Carson Richard E, Gettinger Scott, Smit Egbert F, Boellaard Ronald, de Langen Adrianus J
Аннотация
PURPOSE: Predicting response to checkpoint inhibitors in non-small cell lung cancer (NSCLC) remains challenging. In addition to programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), PD-L1 imaging could improve response prediction. This study evaluated a novel PD-L1 PET tracer, 18F-BMS-986,229, and compared its performance to 18F-BMS-986,192, which shares the same target.
METHODS: Stage IV NSCLC patients were scheduled for baseline PET/CT scans with both tracers. Tracer uptake was quantified using SUVpeak and SUVmean. Imaging findings were correlated with PD-L1 expression from tumor biopsies and clinical outcomes, including best overall response and overall survival.
RESULTS: 18F-BMS-986,192 and 18F-BMS-986,229 performed equally with respect to tumor tracer uptake. Mean SUVpeak was 2.75 (SD 1.53) vs. 2.68 (SD 1.78), p = 0.780. Tumor tracer uptake did not correlate with PD-L1 IHC, mean SUVpeak in the PD-L1 tps < 50% group was 3.77 vs. 3.54 in the PD-L1 ≥ 50% group (p = 0.8175). Explorative analysis of the association between tumor tracer uptake and OS revealed that a low SUVpeak excluded a long OS, whereas a higher SUVpeak did not discriminate between patients with a short or long OS.
CONCLUSION: 18F-BMS-986,229 and 18F-BMS-986,192 performed equally with respect to tumor uptake. In this small cohort, baseline PD-L1 tracer uptake did not correlate with PD-L1 IHC. Low tumor tracer uptake may be associated with shorter overall survival, warranting further investigation.
CLINICAL TRIAL REGISTRATION: NCT03001882, https//clinicaltrials.gov/study/NCT03001882.
METHODS: Stage IV NSCLC patients were scheduled for baseline PET/CT scans with both tracers. Tracer uptake was quantified using SUVpeak and SUVmean. Imaging findings were correlated with PD-L1 expression from tumor biopsies and clinical outcomes, including best overall response and overall survival.
RESULTS: 18F-BMS-986,192 and 18F-BMS-986,229 performed equally with respect to tumor tracer uptake. Mean SUVpeak was 2.75 (SD 1.53) vs. 2.68 (SD 1.78), p = 0.780. Tumor tracer uptake did not correlate with PD-L1 IHC, mean SUVpeak in the PD-L1 tps < 50% group was 3.77 vs. 3.54 in the PD-L1 ≥ 50% group (p = 0.8175). Explorative analysis of the association between tumor tracer uptake and OS revealed that a low SUVpeak excluded a long OS, whereas a higher SUVpeak did not discriminate between patients with a short or long OS.
CONCLUSION: 18F-BMS-986,229 and 18F-BMS-986,192 performed equally with respect to tumor uptake. In this small cohort, baseline PD-L1 tracer uptake did not correlate with PD-L1 IHC. Low tumor tracer uptake may be associated with shorter overall survival, warranting further investigation.
CLINICAL TRIAL REGISTRATION: NCT03001882, https//clinicaltrials.gov/study/NCT03001882.